Both a threshold concentration and a no-effect concentration were observed, suggesting the existence of a safe level of exposure for this potent allergenic chemical (Karol, 1986)
Oral GLP-1 agonists, led by oral Semaglutide, are gaining momentum as they offer greater convenience and patient adherence
An EY consumer products expert estimated last year that approximately 10 percent of the U.S
Dysaesthesia has been reported in some clinical trials of semaglutide, including the STEP UP T2D trial of subcutaneous semaglutide, results of which showed that the adverse effect was more common with 7.2 mg doses (n=58 [18.9%] of 307) compared with 2.4 mg doses (n=five [4.9%] of 103)
California Consortium of Addiction Programs and Professionals (CCAPP) This educational program is approved by CCAPP: #OS-20-330-1224
Therefore, having a robust IP strategy in place to protect the pipeline of potential drugs will be crucial for any company
